Potent δ-opioid receptor agonists containing the Dmt-Tic pharmacophore

Journal of Medicinal Chemistry

Volumn 45, Issue 25, 2002, Pages 5556-5563

  Balboni, Gianfranco ^a   Salvadori, Severo ^b   Guerrini, Remo ^b   Negri, Lucia ^c   Giannini, Elisa ^c   Jinsmaa, Yunden ^d   Bryant, Sharon D ^d   Lazarus, Lawrence H ^d  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,4 TETRAHYDROISOQUINOLINE 3 CARBOXYLIC ACID; 1H BENZIMIDAZOL 2 YL; 2',6' DIMETHYLTYROSINE; AMIDE; AMINO ACID; AROMATIC COMPOUND; ASPARAGINE; ASPARTIC ACID; ASPARTIC ACID DERIVATIVE; BENZIMIDAZOLE DERIVATIVE; CARBOXYLIC ACID DERIVATIVE; DELTA OPIATE RECEPTOR; DELTA OPIATE RECEPTOR AGONIST; DELTA OPIATE RECEPTOR ANTAGONIST; LINK PROTEIN; TYROSINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CHEMICAL STRUCTURE; DRUG POTENCY; IC 50; PHARMACOPHORE;

ANIMALS; BENZIMIDAZOLES; BINDING, COMPETITIVE; BRAIN; DIPEPTIDES; ELECTRIC STIMULATION; GUINEA PIGS; INTESTINE, SMALL; MODELS, MOLECULAR; MUSCLE CONTRACTION; MUSCLE, SMOOTH; MYENTERIC PLEXUS; NEUROMUSCULAR JUNCTION; RADIOLIGAND ASSAY; RATS; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, MU; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAHYDROISOQUINOLINES;

EID: 0037028032     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm020336e     Document Type: Article

References (46)

1. 3CN, sodium cyanoborohydride; NMM, 4-methylmorpholine; NTI, naltrindole; NH-tBut, tert-butylamine; OMe, methyl ester; Pe, petroleum ether; Ph, phenyl; TEA, triethylamine; TFA, trifluoroacetic acid; Tic, 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; TIP(P), H-Tyr-Tic-Phe-(Phe)-OH; TLC, thin-layer chromatography; WSC, 1-ethyl-3-[(3′-dimethyl)aminopropyl]carbodiimide hydrochloride; Z, benzyloxycarbonyl.
2. Salvadori, S.; Balboni, G.; Guerrini, R.; Tomatis, R.; Bianchi, C.; Bryant, S. D.; Cooper, P. S.; Lazarus, L. H. Evolution of the Dmt-Tic pharmacophore: N-terminal methylated derivatives with extraordinary δ opioid antagonist activity. J. Med. Chem. 1997, 40, 3100-3108.
3. Salvadori, S.; Guerrini, R.; Balboni, G.; Bianchi, C.; Bryant, S. D.; Cooper, P. S.; Lazarus, L. H. Further studies on the Dmt-Tic pharmacophore: Hydrophobic substituents at the C-terminus endows δ antagonists to manifest μ agonism or μ antagonism. J. Med. Chem. 1999, 42, 5010-5019.
4. Balboni, G.; Guerrini, R.; Salvadori, S.; Bianchi, C.; Rizzi, D.; Bryant, S. D.; Lazarus, L. H. Evaluation of the Dmt-Tic pharmacophore: Conversion of a potent δ-opioid receptor antagonist into a potent δ-agonist and ligands with mixed properties. J. Med. Chem. 2002, 45, 713-720.
5. Pagé, D.; Naismith, A.; Schmidt, R.; Coupal, M.; Labarre, M.; Gosselin, M.; Bellemare, D.; Payza, K.; Brown, W. Novel C-terminus modifications of the Dmt-Tic motif: A new class of dipeptide analogues showing altered pharmacological profiles toward the opioid receptors. J. Med. Chem. 2661, 44, 2387-2390.
6. Salvadori, S.; Attila, M.; Balboni, G.; Bianchi, C.; Bryant, S. D.; Crescenzi, O.; Guerrini, R.; Picone, D.; Tancredi, T.; Temussi, P. A.; Lazarus, L. H. δ opioidmimetic antagonists: Prototypes for designing a new generation of ultraselective opioid peptides. Mol. Med. 1995, 1, 678-689.
7. Chandrakumar, N. S.; Stapelfeld, A.; Beardsley, P. M.; Lopez, O. T.; Drury, B.; Anthony, E.; Savage, M. A.; Williamson, L. N.; Reichman, M. [2-D-penicillamine,5-D-penicillamine]-enkephalin: 2′,6′-dimethyltyrosine and Gly3-Phe4 amide bond isostere substitutions. J. Med. Chem. 1992, 35, 2928-2938.
8. Schiller, P. W.; Weltrowska, G.; Schmidt, R.; Nguyen, T. M.-D.; Berezowska, I.; Lemieux, C.; Chung, N. N.; Carpenter, K. A.; Wilkes, B. C. Four different types of opioid peptides with mixed μ agonist/δ antagonist properties. Analgesia 1995, 1, 703-706.
9. 1]deltorphin B. Eur. J. Pharmacol. 1996, 302, 37-42.
10. Guerrini, R.; Capasso, A.; Marastoni, A.; Bryant, S. D.; Cooper, P. S.; Lazarus, L. H.; Temussi, P. A.; Salvadori, S. Rational design of dynorphin A analogues with δ-receptor selectivity and antagonism for δ- and κ-receptors. Bioorg. Med. Chem. 1998, 6, 57-62.
11. Lazarus, L. H.; Bryant, S. D.; Cooper, P. S.; Salvadori, S. What peptides these deltorphins be. Prog. Neurobiol. 1999, 57, 377-420.
12. Sasaki, Y.; Suto, T.; Ambo, A.; Ouchi, H.; Yamamoto, Y. Biological properties of opioid peptides replacing Tyr at position 1 by 2,6-dimethyl-Tyr. Chem. Pharm. Bull. 1999, 47, 1506-1507.
13. 2[ψ] produces a potent analgesic effect, no physical dependence, and less tolerance than morphine in rats. J. Med. Chem. 1999, 42, 3520-3526.
14. Santagada, V.; Balboni, G.; Caliendo, G.; Guerrini, R.; Salvadori, S.; Bianchi, C.; Bryant, S. D.; Lazarus, L. H. Assessment of substitution in the second pharmacophore of Dmt-Tic analogues. Bioorg. Med. Chem. Lett. 2000, 10, 2745-2748.
15. Schiller, P. W.; Nguyen, T. M.-D.; Berezowska, I.; Dupuis, S.; Weltrowska, G.; Chung, N. N.; Lemieux, C. Synthesis and in vitro opioid activity profiles of DALDA analogues. Eur. J. Med. Chem. 2000, 35, 895-901.
16. Balboni, G.; Salvadori, S.; Guerrini, R.; Bianchi, C.; Santagada, V.; Calliendo, G.; Bryant, S. D.; Lazarus, L. H. Opioid pseudopeptides containing heteroaromatic or heteroaliphatic nuclei. Peptides 2000, 21, 1663-1671.
17. Pagé, D.; McClory, A.; Mischki, T.; Schmidt, R.; Butterworth, J.; St-Onge, S.; Labarre, M.; Payza, K.; Brown, W. Novel Dmt-Tic dipeptide analogues as selective delta-opioid receptor antagonists. Bioorg. Med. Chem. Lett. 2000, 10, 167-170.
18. Fujita, Y.; Takahashi, M.; Yokoi, T.; Tsuda, Y.; Lazarus, L. H.; Bryant, S. D.; Anbo, A.; Sasaki, Y.; Okada, Y. Development of endomorphin derivatives with dual functions and studies on their three-dimensional structure. In American Peptide Symposium; Lebl, M., Houghten, R. A.; Eds.; American Peptide Society: San Diego, CA, 2001.
19. i3 transducer proteins. Life Sci. 1993, 53, PL129-PL134.
20. i2 Transducer proteins on μ/δ opioid-mediated supraspinal antinociception. Life Sci. 1993, 53, PL381-PL386.
21. Chetsawang, B.; Casolotti, S. O.; Phansuwan-Pujito, P.; Kotchabhakdi, N.; Govitrapong, P. Gene expressions of opioid receptors and G-proteins in pineal glands. Biochem. Biophys. Res. Commun. 1999, 262, 775-780.
22. Sanchez-Blazquez, P.; Rodriguez-Diaz, M.; deAntonio, I.; Garzon, J. Endomorphin-1 and endomorphin-2 show differences in their activation of μ opioid receptor-regulated G proteins in supraspinal antinociception in mice. J. Pharmacol. Exp. Ther. 1999, 291, 12-19.
23. Topham, C. M.; Mouledous, L.; Meunier, J.-C. On the spatial disposition of the fifth transmembrane helix and the structural integrity of the transmembrane binding site in the opioid and ORL G protein-coupled receptor family. Protein Eng. 2000, 13, 477-490.
24. Jordan, R. A.; Cvejic, S.; Devi, L. A. Opioids and their complicated receptor complexes. Neuropsychopharmacology 2000, 23, S5-S18.
25. Lazarus, L. H.; Bryant, S. D.; Cooper, P. S.; Guerrini, R.; Balboni, G.; Salvadori, S. Design of δ-opioid peptide antagonists for emerging drug applications. Drug Discovery Today 1998, 3, 284-294.
26. Lazarus, L. H.; Salvadori, S.; Santagada, V.; Tomatis, R.; Wilson, W. E. Function of negative charge in the "address domain" of deltorphins. J. Med. Chem. 1991, 34, 1350-1359.
27. 4 in deltorphin A for high δ opioid receptor selectivity. Amino Acids 1994, 7, 291-304.
28. Marastoni, M.; Fantin, G.; Bortolotti, F.; Tomatis, R. Synthesis and activity of pseudotripeptides inhibitors of HIV-1 protease containing D(-)-O-(benzyl)tartaric acid. Arzneim.-Forsch. 1996, 46, 1099-1101.
29. (a) Bryant, S. D.; Salvadori, S.; Cooper, P. S.; Lazarus, L. H. New δ opioid antagonists as pharmacological probes. Trends Pharmacol. Sci. 1998, 19, 42-46.
30. (b) Bryant, S. D.; George, C.; Flippen-Anderson, J. L.; Deschamps, J. R.; Salvadori, S.; Balboni, G.; Guerrini, R.; Lazarus, L. H. Crystal structures of dipeptides containing the Dmt-Tic pharmacophore. J. Med. Chem., in press.
31. (c) Bryant, S. D.; Salvadori, S.; Okada, Y.; Takahashi, M.; Sasaki, Y.; Lazarus, L. H. Computational chemistry and opioidmimetics: Receptor ligand interaction of three classes of biologically potent peptides. In Peptides 2000; Martinez, J., Fehrentz, J.-A., Eds.; Editions EDK: Paris, 2000; pp 407-408.
32. Hruby, V. J.; Gehrig, C. Recent developments in the design of receptor specific opioid peptides. Med. Res. Rev. 1989, 9, 343-401.
33. 1 replacement in the cyclic δ receptor selective tetrapeptide Try-c[D-Cys-Phe-D-Pen]OH (JOM-13). J. Med. Chem. 1994, 37, 4371-4383.
34. 3 replacements in the cyclic δ receptor selective tetrapeptide Tyr c[D-Cys-Phe-D-Pen]OH (JOM-13). J. Med. Chem. 1994, 37, 4384-4391.
35. Lomize, A. I.; Pogozheva, I.; Mosberg, H. I. Development of a model for the δ-opioid receptor pharmacophore: 3. Comparison of the cyclic tetrapeptide Try-C[D-Cys-Phe-D-Pen]OH with other conformationally constrained δ-receptor selective ligands. Biopolymers 1996, 38, 221-234.
36. Labarre, M.; Butterworth, J.; St-Onge, S.; Payza, K.; Schmidhammer, H.; Salvadori, S.; Balboni, G.; Guerrini, R.; Bryant, S. D.; Lazarus, L. H. Inverse agonism by Dmt-Tic analogues and HS 378, a naltrindole analogue. Eur. J. Pharmacol. 2000, 406, R1-R3.
37. Temussi, P. A.; Salvadori, S.; Amodeo, P.; Bianchi, C.; Guerrini, R.; Tomatis, R.; Lazarus, L. H.; Tancredi, T. Selective opioid dipeptides. Biochem. Biophys. Res. Commun. 1994, 198, 933-939.
38. Schiller, P. W.; Wltrowska, G.; Schmidt, R.; Berezowska, I.; Nguyen, T. M.-D.; Lemieux, C.; Chung, N. N.; Carpenter, K. A.; Wilkes, B. C. Subtleties of structure-agonist versus antagonist relationships of opioid peptides and peptidomimetics. J. Recept. Signal Transduction Res. 1999, 19, 573-588.
39. Schiller, P. W.; Weltroska, G.; Berezowska, I.; Nguyen, T. M.-D.; Wilkes, B. C.; Lemieux, C.; Chung, N. N. The TIPP opioid peptide family: Development of δ antagonists, δ agonists, and mixed μ agonists/δ antagonists. Biopolymers 1999, 51, 411-425.
40. Dygos, J. H.; Yonan, E. E.; Scaros, M. G.; Goodmonson, O. J.; Getman, D. P.; Periana, R. A.; Beck, G. R. A convenient asymmetric synthesis of the unnatural amino acid 2,6-dimethyl-L-tyrosine. Synthesis. 1992, 8, 741-743.
41. Cescon, L. A.; Day, A. R. Preparation of some benzimidazolyl-amino acids. Reactions of amino acids with o-phenylenediamines. J. Org. Chem. 1962, 27, 581-586.
42. Melchiorri, P.; Negri, L. The dermorphin peptide family. Gen. Pharmacol. 1996, 27, 1099-1107.
43. Lazarus, L. H.; Guglietta, A.; Wilson, W. E.; Irons, B. J.; de Castiglione, R. Dimeric dermorphin analogues as μ-receptor probes on rat brain membranes. Correlation between central μ-receptor potency and suppression of gastric acid secretion. J. Biol. Chem. 1989, 264, 354-362.
44. 50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.
45. Chang, J.; Fong, B. Opiate receptor affinities and behavioral effects of enkephalin: Structure-activity relationship of 10 synthetic peptide analogues. Life Sci. 1976, 18, 1473-1482.
46. 3 deltorphin analogues: Enhanced selectivity of halogenated derivatives for δ opioid receptor sites. J. Med. Chem. 1992, 35, 4651-4657.